FLGT Fulgent Genetics Inc

Price (delayed)

$52.72

Market cap

$1.6B

P/E Ratio

4.04

Dividend/share

N/A

EPS

$13.06

Enterprise value

$1.48B

Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high ...

Highlights
The company's equity rose by 43% YoY
The price to earnings (P/E) is 12% lower than the last 4 quarters average of 4.6
FLGT's quick ratio is up by 16% year-on-year but it is down by 3.2% since the previous quarter
FLGT's EPS is down by 31% year-on-year and by 15% since the previous quarter
The net income has contracted by 20% YoY and by 15% from the previous quarter

Key stats

What are the main financial stats of FLGT
Market
Shares outstanding
30.27M
Market cap
$1.6B
Enterprise value
$1.48B
Valuations
Price to earnings (P/E)
4.04
Price to book (P/B)
1.23
Price to sales (P/S)
1.73
EV/EBIT
2.8
EV/EBITDA
2.68
EV/Sales
1.6
Earnings
Revenue
$925.15M
EBIT
$528.14M
EBITDA
$550.41M
Free cash flow
$410.89M
Per share
EPS
$13.06
Free cash flow per share
$13.53
Book value per share
$43.02
Revenue per share
$30.47
TBVPS
$41.19
Balance sheet
Total assets
$1.46B
Total liabilities
$150.93M
Debt
$20.79M
Equity
$1.3B
Working capital
$547.66M
Liquidity
Debt to equity
0.02
Current ratio
5.29
Quick ratio
5.09
Net debt/EBITDA
-0.21
Margins
EBITDA margin
59.5%
Gross margin
73.7%
Net margin
42.4%
Operating margin
56.7%
Efficiency
Return on assets
29%
Return on equity
32.7%
Return on invested capital
58.2%
Return on capital employed
39.6%
Return on sales
57.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FLGT stock price

How has the Fulgent Genetics stock price performed over time
Intraday
-11.93%
1 week
-11.45%
1 month
-10.45%
1 year
-50.15%
YTD
-47.59%
QTD
-3.32%

Financial performance

How have Fulgent Genetics's revenue and profit performed over time
Revenue
$925.15M
Gross profit
$681.76M
Operating income
$524.86M
Net income
$392.38M
Gross margin
73.7%
Net margin
42.4%
Fulgent Genetics's net margin has decreased by 22% YoY and by 12% from the previous quarter
Fulgent Genetics's operating margin has decreased by 21% YoY and by 12% from the previous quarter
The net income has contracted by 20% YoY and by 15% from the previous quarter
Fulgent Genetics's operating income has decreased by 20% YoY and by 14% from the previous quarter

Growth

What is Fulgent Genetics's growth rate over time

Valuation

What is Fulgent Genetics stock price valuation
P/E
4.04
P/B
1.23
P/S
1.73
EV/EBIT
2.8
EV/EBITDA
2.68
EV/Sales
1.6
FLGT's EPS is down by 31% year-on-year and by 15% since the previous quarter
The price to earnings (P/E) is 12% lower than the last 4 quarters average of 4.6
The price to book (P/B) is 49% lower than the 5-year quarterly average of 2.4 and 39% lower than the last 4 quarters average of 2.0
The company's equity rose by 43% YoY
FLGT's P/S is 60% below its 5-year quarterly average of 4.3 and 25% below its last 4 quarters average of 2.3
Fulgent Genetics's revenue has decreased by 3% QoQ

Efficiency

How efficient is Fulgent Genetics business performance
The return on equity has dropped by 59% year-on-year and by 22% since the previous quarter
The company's return on assets has shrunk by 56% YoY and by 21% QoQ
The company's return on invested capital has shrunk by 53% YoY and by 19% QoQ
FLGT's ROS is down by 21% year-on-year and by 12% since the previous quarter

Dividends

What is FLGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLGT.

Financial health

How did Fulgent Genetics financials performed over time
Fulgent Genetics's total assets has increased by 39% YoY
Fulgent Genetics's total liabilities has increased by 17% YoY
Fulgent Genetics's debt is 98% less than its equity
The company's equity rose by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.